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1455Evolving Therapies for
Myocardial Ischemia/Reperfusion InjuryABSTRACTThe damage inﬂicted on the myocardium during acute myocardial infarction is the result of 2 processes: ischemia and
subsequent reperfusion (ischemia/reperfusion injury). During the last 3 decades, therapies to reduce ischemic injury
(mainly reperfusion strategies) have been widely incorporated into clinical practice. The remarkable reduction in death
rates achieved with these therapies has resulted in a shift in emphasis from efforts to reduce mortality to a focus on
tackling the downstream consequence of survival: post-infarction heart failure. Infarct size is the main determinant of
long-term mortality and chronic heart failure, and thus, the possibility of limiting the extent of necrosis during an
ST-segment elevation myocardial infarction is of great individual and socioeconomic value. After the great success of
therapies to reduce ischemic injury, the time has come to focus efforts on therapies to reduce reperfusion injury, but
in the recent few years, few interventions have successfully passed the proof-of-concept stage. In this review, we
examine the past, present, and future therapies to reduce ischemia/reperfusion injury. (J AmColl Cardiol 2015;65:1454–71)
© 2015 by the American College of Cardiology Foundation.A cute myocardial infarction presenting as ST-segment elevation (STEMI) is the result ofabrupt occlusion of an epicardial coronary ar-
tery. As a result, the myocardium distal to the occlu-
sion site becomes ischemic. Unrelieved ischemia
causes permanent damage to the myocardium previ-
ously supplied by the occluded artery. Myocardium
is destroyed and replaced by ﬁbrous scar tissue.
Because scar tissue does not contribute to myocardial
contractile function, if the scar is large, global left
ventricular (LV) contractile function is impaired,
resulting in progressive chronic heart failure. After
the demonstration that coronary thrombosis was the
cause (not the result) of STEMI in the vast majority
of cases, timely restoration of blood ﬂow to the
ischemic myocardium (reperfusion) became the stan-
dard treatment for these patients. Reperfusion was
rapidly demonstrated to limit infarct size, improve
long-term myocardial function, change the healing
pattern of the infarcted zone, and more importantly,
reduce mortality. A large body of experimental and
clinical evidence supports the notion that reperfusion
induces additional damage to the myocardium,
known as reperfusion injury. As a result, the damage
inﬂicted on the myocardium during an STEMI is
better deﬁned as ischemia/reperfusion (I/R) injury,
the result of ischemic and reperfusion processes.
Myocardial I/R injury is a complex phenomenon
involving many players, all contributing to the ﬁnal
damage inﬂicted on the heart (Central Illustration).
In the present review, we describe the evolving
therapies for the treatment of myocardial I/R injury.
These include therapies targeting both ischemic andreperfusion damage. To explain the rationale for the
quest for new and better therapies, we describe
the pathophysiology of myocardial I/R injury and the
translational path of research, from the pre-clinical
discovery phase, through proof-of-concept clinical
trials, to large trials aimed at changing clinical prac-
tice. In the context of this paper, the term myocardial
infarction always refers to STEMI.
IMPACT OF STEMI IN 2015:
A PARADIGM SHIFT
The incidence of STEMI in Western countries has
declined during the last decades due to the progres-
sive implementation of preventive therapies and
better control of risk factors (1). Despite the progres-
sive and gradual decrease in its incidence, STEMI re-
mains a signiﬁcant health problem, representing a
major contributor to mortality/morbidity worldwide
(1). As detailed later in this review, the implementa-
tion of timely reperfusion has resulted in a very sig-
niﬁcant reduction in the acute mortality associated
with STEMI. Risk-adjusted in-hospital mortality has
decreased fromz20% in the late 1980s toz5% among
STEMI patients treated in routine practice in 2008
(2), reaching a plateau thereafter (3). However, these
impressive reductions in mortality rates, resulting
from the widespread use of reperfusion strategies and
adjuvant pharmacological therapies, have resulted in
an increase in the incidence of chronic heart failure.
Although this outcome might at ﬁrst seem paradoxi-
cal, the explanation is simple: patients with a severely
depressed cardiac function would not have survived
ABBR EV I A T I ON S
AND ACRONYMS
AAR = area at risk
CMR = cardiac magnetic
resonance
I/R = ischemia/reperfusion
LVEF = left ventricular
ejection fraction
MPTP = mitochondrial
permeability transition pore
MVO = microvascular
obstruction
PCI = percutaneous coronary
intervention
STEMI = ST-segment elevation
myocardial infarction
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the advent of reperfusion, they now survive
the index episode and live with a signiﬁcantly
damaged heart (2). In fact, STEMI is 1 of the
major contributors to chronic heart failure.
Post-infarction reduced left ventricular ejec-
tion fraction (LVEF) is 1 of the principal cau-
ses of chronic heart failure worldwide (4).
The great success of reperfusion therapies
has resulted in a paradigm shift in clinical
research in the ﬁeld of STEMI: attention is
no longer solely aimed toward reducing
mortality (already very low), but increas-
ingly, is to tackle the downstream conse-
quence of improved survival: post-infarction
heart failure.Successful clinical research has led to inter-
ventions for chronic heart failure (drugs and devices)
that reduce long-term mortality in STEMI survivors
with low LVEF (5). However, these strategies are
economically costly, precluding their universal im-
plementation (6). Chronic treatment of heart failure
represents a huge socioeconomic burden on in-
dividuals and health care systems. As explained
later in this paper, infarct size is the main deter-
minant of adverse post-infarction outcomes, in-
cluding heart failure (7). Therapies able to reduce
infarct size are, therefore, urgently sought under the
hypothesis that smaller infarctions will result in
better long-term heart performance and that this
will translate into fewer adverse clinical events
(8,9). As we detail throughout this paper, the iden-
tiﬁcation of reﬁned or new therapies better able to
reduce infarct size is a major challenge to 21st
century society.
PATHOPHYSIOLOGY OF I/R INJURY
GENERAL CONSIDERATIONS. After the occlusion of
an epicardial coronary artery, the myocardium previ-
ously perfused by the occluded artery is in jeopardy.
The hypoperfused myocardial zone during myocardial
infarction is known as the area at risk (AAR). If the
coronary artery is not rapidly reperfused and no
collateral circulation is present, most of the AAR
becomes necrotic. Given that many patients receive
timely reperfusion therapy, part of the AAR remains
free of necrosis: the so-called salvaged myocardium.
The typical morphological features of reperfused
myocardial infarction are contraction bands, kar-
yolysis, mitochondrial swelling and disruption, and
membrane disruption in cardiomyocytes, accompa-
nied by microvascular destruction, interstitial hem-
orrhage, and inﬂammation (10,11). Experimentalstudies identiﬁed the determinants of myocardial
infarct size as: 1) the size of the AAR (12); 2) the
duration of myocardial ischemia (13,14); 3) the amount
of residual blood ﬂow through collaterals (12,13);
4) the temperature of the tissue during ischemia; and
5) the hemodynamic situation during ischemia (15).
The most notable hemodynamic parameter is heart
rate, which determines not only myocardial demand,
but also coronary blood ﬂow (16); however, hemody-
namics inﬂuence infarct size only to a limited degree,
and infarct size is, thus, largely determined by lack of
blood/energy supply and less by myocardial demand,
which is signiﬁcantly reduced by the regional lack of
contraction (17).
The seminal studies by Maroko et al. (18) and Ginks
et al. (19) 40 years ago ﬁrst demonstrated that
reperfusion salvages myocardium from infarction,
and these studies initiated the ongoing success story
of reperfusion therapy (20). The potential of reper-
fusion to induce additional injury secondary to the
ischemic damage emerged soon afterward with the
identiﬁcation of stunning as a reversible form of
myocardial reperfusion injury (21). Although the
contribution of reperfusion injury to ﬁnal infarct size
has been disputed in the past, today it is accepted
that reperfusion can induce additional damage to the
myocardium. This view is supported by strong evi-
dence that interventions applied at the end of the
ischemic period (i.e., coinciding with reperfusion) can
reduce infarct size. It was already recognized in the
mid-1980s that gentle reperfusion at low pressure
resulted in signiﬁcantly less edema and a smaller
infarct size than standard abrupt reperfusion at
normal pressure (22). This idea was later developed
by Zhao et al. (23), who demonstrated reduction of
infarct size by brief episodes of coronary reocclusion/
reﬂow at the time of reperfusion, a strategy called
ischemic post-conditioning (24). Because these in-
terventions are applied at the end of the ischemic
period, they cannot reduce infarct size by reducing
ischemic damage and, thus, must reduce reperfusion-
related damage. From these observations it is clear
not only that reperfusion injury contributes to infarct
size, but also that all conditioning strategies that
protect the myocardium and reduce infarct size
act only in conjunction with eventual reperfusion
(8,25,26).
ROLE OF MICROCIRCULATION IN INFARCT SIZE
AFTER STEMI. The coronary microcirculation is a
critical player in the complex phenomenon of
myocardial I/R (Central Illustration). The microcircu-
latory network is the interface between the epicardial
vessel and the cardiomyocytes. Thus, no matter how
J A C C V O L . 6 5 , N O . 1 4 , 2 0 1 5 Ibáñez et al.
A P R I L 1 4 , 2 0 1 5 : 1 4 5 4 – 7 1 Evolving Therapies for Myocardial I/R Injury
1457efﬁciently and rapidly the blood ﬂow is restored to
the epicardial artery, if there is a microvascular
obstruction (MVO) the myocardial tissue will remain
without efﬁcient perfusion. MVO (also termed the no-
reﬂow phenomenon) during I/R is a major contributor
to ﬁnal infarct size and is an independent predictor of
morbidity/mortality (27). The no-reﬂow phenomenon
was ﬁrst characterized by Kloner et al. (11,28) in dogs
subjected to 90 min of coronary occlusion and sub-
sequent reperfusion; the coronary microcirculation
of these animals showed severe capillary damage,
notably swollen and ruptured endothelial cells, and
intraluminal thrombosis, and was surrounded by
swollen and irreversibly injured cardiomyocytes. In
the clinic, the no-reﬂow phenomenon is seen in 10%
to 30% of patients with reperfused STEMI (29,30)
despite successful recanalization of the epicardial
coronary arteries; MVO in these patients is detected
angiographically from slow or no reﬂow of contrast
medium or by cardiac magnetic resonance (CMR).
MVO develops within minutes of established reper-
fusion (31,32) and persists for at least 1 week (33,34).
MVO is usually conﬁned to the infarcted myocardium
(14,28); however, the existence of no-reﬂow pheno-
mena within the AAR but outside the infarcted area
has not been systematically excluded. Notably, MVO
can impair the washout of reduction equivalents and
dehydrogenases that is mandatory for valid delinea-
tion of infarcted tissue by TTC staining, thus con-
tributing to underestimation of infarct size (35).
Reduced coronary blood ﬂow is also observed outside
of the AAR, but this does not reﬂect a no-reﬂow
phenomenon, and is instead the result of reﬂex-
mediated alpha-adrenergic coronary vasoconstric-
tion (36–38).
A number of mechanisms have been proposed as
contributors to MVO: 1) embolization of particulate
debris from the ruptured culprit atherosclerotic
lesion, with physical obstruction of the coronary
microcirculation (39); 2) platelet and platelet/leuko-
cyte aggregates that are released from the site of the
culprit lesion, form in the coronary microcirculation,
or arrive with the blood ﬂow, where they form as part
of the general inﬂammatory status associated with
STEMI (40); 3) intense vasoconstriction induced
by soluble vasoconstrictor substances released from
the culprit lesion (41,42); 4) extravascular coronary
microvascular compression due to edema in the sur-
rounding myocardium (43); and 5) primary physical
destruction of the capillary endothelium (28). These
different mechanisms are not mutually exclusive and
can act in concert, and their individual contribution
to impaired myocardial reperfusion may vary
temporally and spatially. Irreversible injury tocardiomyocytes and the coronary microcirculation
are intimately related (44). High intramyocardial
pressure, with a predominant contribution from
edema, might be the principal cause of MVO in the
endocardial layer, whereas microembolization might
underlie infarct expansion in the border zone (45).
However, there is currently no evidence to support a
causal role for microvascular coronary obstruction in
myocardial infarction, although it is intuitive to argue
that the absence of efﬁcient tissue perfusion in areas
of MVO will maintain the muscle ischemia and thus
contribute to infarct expansion.
The role of leukocytes in myocardial infarct devel-
opment is contentious, and leukocyte inﬁltration may
be more important for infarct healing and remodeling
rather than the determination of infarct size (46).
However, the potential contribution of intravascular
leukocytes to MVO and infarct size deserves more
attention. Myocardial infarction and MVO currently
appear to be parallel phenomena that result from
similar pathomechanisms: a primary energetic deﬁcit
and subsequent excessive formation of reactive oxy-
gen species upon reperfusion. It is, therefore, not
surprising that post-conditioning reduces not only
myocardial infarct size, but also MVO (23,34).
CARDIOMYOCYTE NECROSIS, APOPTOSIS, AUTOPHAGY,
AND NECROPTOSIS: DOES MODE OF DEATH MATTER?
Myocardial infarction has traditionally been viewed
as a manifestation of necrotic cell death, but recently,
different forms of cardiomyocyte death have been
identiﬁed during I/R and are proposed to contribute
to ﬁnal infarct size.
Necrosis is morphologically characterized by myo-
ﬁbrillar contraction bands, swollen and ruptured
mitochondria, destruction of cardiomyocyte mem-
branes, microvascular destruction, hemorrhage, and
inﬂammation. Most of these morphological features
are aggravated and are made more manifest by reper-
fusion (11,13,14,47,48). Necrosis is thought to result
from unregulated and uncoordinated pathophysio-
logical mechanisms. During ischemia, the developing
acidosis from anaerobic glycolysis increases the inﬂux
of Naþ through the Naþ/Hþ-exchanger, and intracel-
lular Naþ accumulation is increased by the inhibition
of Naþ/Kþ-ATPase due to the lack of available ATP
(49,50). The subsequent exchange of Naþ for Caþþ by
reverse mode operation of the sarcolemmal Naþ/Caþþ-
exchanger induces intracellular Caþþ overload. Upon
reperfusion, the rapid normalization of pH and re-
energization in the context of elevated cytosolic Caþþ
induces oscillatory release and reuptake of Caþþ into
the sarcoplasmic reticulum, causing uncontrolled
excess myoﬁbrillar hypercontraction (50–52). The
Continued on the next page
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1459normalization of the acidic pH also activates calpain,
which digests the cytoskeleton and the sarcolemma
(53). The high cytosolic concentrations of Naþand Caþþ
result in intracellular edema when extracellular
osmolarity is rapidly normalized by reperfusion.
Finally, excess formation of reactive oxygen species
contributes to sarcolemmal disruption (54). Necrosis is
typically followed by an inﬂammatory response.
Unlike necrosis, apoptosis, autophagy, and nec-
roptosis are regulated processes with speciﬁc un-
derlying signal transduction mechanisms (55,56).
Apoptosis is an energy-consuming form of cell death
characterized by characteristic deoxyribonucleic acid
strand breaks that are identiﬁed by deoxyribonucleic
acid laddering and/or terminal deoxynucleotidyl
transferase dUTP nick-end labeling staining (57).
Apoptosis can be initiated extrinsically by activation
of sarcolemmal receptors, notably FAS and tumor ne-
crosis factor a receptors (58), or intrinsically
by mitochondrial release of cytochrome c, which
initiates a cascade of caspase activation leading to
intracellular proteolysis, typically without an inﬂam-
matory response (56). A pivotal event in the initiation
of apoptotic cell death is the opening of the mito-
chondrial permeability transition pore (MPTP) (59).
The MPTP is a large-conductance megachannel, which
is closed under physiological conditions but opens in
response to increased concentrations of calcium,
inorganic phosphate, or reactive oxygen species and
to a decreased inner mitochondrial membrane poten-
tial, all of which are present in myocardial I/R
(60,61). Formation and opening of the MPTP results in
mitochondrial matrix swelling, ultimately leading to
rupture of the outer membrane and release of cyto-
chrome c to the cytosol, where it activates the caspaseMyocardial ischemia/reperfusion injury is a complex phenomenon in wh
myocardium. 1. The ﬁrst critical player is the epicardial artery. Atheroscle
stop of oxygen and nutrient supply distal to the occlusion site. The open
as well as the thrombus burden reduction by adjuvant antiplatelet/antic
myocardium. During the reperfusion process (either if it is mechanical by
material and other plaque debris can be distally embolized contributing
damage inﬂicted to the myocardium: activated platelet and leukocytes in
also can form plugins that can embolize distally into the microcirculatio
pendent from plaque debris microembolization). 3. The microcirculation
during ischemia/reperfusion. Once the epicardial vessel ﬂow is restored
Plaque debris and platelet/neutrophil aggregates can induce a mechani
perfusion. The generation of tissue edema following reperfusion can re
perfusion capacity of the capillary network (double arrows). Finally, th
allow the leakiness of circulating cells into the interstitial space. 4. Red
release of iron, contributing to the subsequent inﬂammatory reaction. 5
the reperfusion period due to several intracellular pathways triggered at
6. After the entire ischemia/reperfusion insult has passed, the signiﬁcan
additional damage to the myocardium.
CENTRAL ILLUSTRATIONcascade. Proapoptotic and antiapoptotic proteins of
the Bcl-family interact with the MPTP (62). Recently,
the traditional view of the MPTP has been questioned,
because all of its purported constituents are dispens-
able under some conditions, and it is possible that the
MPTP originates from F-ATP synthase (63).
Autophagy is a regulated process of lysosomal
degradation and recycling of proteins, including
mitochondrial proteins (mitophagy) (64). Autophagy
is characterized by the presence of double-membrane
vesicles (autophagosomes) and increased expression
of beclin-1, light chain 3, the autophagy-related gene
5-12 complex, p62, and parkin, the last 2 of which are
essential for mitophagy (65). Somewhat paradoxi-
cally, cell death by autophagy is considered protec-
tive rather than detrimental (66). For example, in pigs
subjected to 45 min of coronary occlusion and
reperfusion, the purported autophagy inducer chlor-
amphenicol reduced infarct size (67). However, the
role of autophagy in myocardial I/R injury in humans
remains contentious (68,69).
Necroptosis shares features with necrosis and
apoptosis, but is distinctly regulated by activation of
receptor-interacting protein kinases 1 and 3 (70) and
can be inhibited by substances such as necrostatin (71).
It is currently unclear to what extent necrosis,
apoptosis, autophagy, and necroptosis are mutually
exclusive processes and to what extent each con-
tributes to infarct size. Typical features of apoptosis
(terminal deoxynucleotidyl transferase dUTP nick-
end labeling staining) and autophagy (characteristic
protein expression) are both found in the TTC
staining-deﬁned infarct zone, which has traditionally
been considered necrotic. The opening of the MPTP
appears to be decisive for necrosis, apoptosis, andich many players contribute to the ﬁnal damage inﬂicted to the
rotic plaque rupture with superimposed thrombus results in an abrupt
ing of the epicardial vessel by mechanical or pharmacological means,
oagulant therapies is only the ﬁrst step toward the salvage of
primary angioplasty or pharmacological by thrombolytics), thrombus
to microvascular obstruction. 2. Circulating cells contribute to the
the bloodstream not only contribute to the thrombus generation, but
n upon resting blood ﬂow across the culprit lesion (a process inde-
(net of capillaries) is a critical player in the fate of the myocardium
, efﬁcient tissue perfusion is dictated mainly by the microcirculation.
cal obstruction of the microcirculation precluding efﬁcient tissue
sult in external compression of the microcirculation, reducing the
e microcirculation can disintegrate due to the previous damage and
blood cell deposits (hemorrhage) are especially harmful due to the
. Cardiomyocytes that have survived the ischemic phase suffer during
reperfusion (see text for detailed information about these processes).
t inﬁltration of myocardial tissue by inﬂammatory cells can induce an
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1460necroptosis, and mitochondria are also decisive in
mitophagy/autophagy. The importance of regulated
forms of cardiomyocyte cell death in I/R injury is
probably related more to their speciﬁc signal trans-
duction mechanisms. Recognition of the different
modes of cardiomyocyte death during infarction
suggests the possibility of identifying therapeutic
targets that can modulate these processes. From the
clinical perspective, cardiomyocyte death is equally
relevant whatever the mechanism.
PRE-CLINICAL MODELS OF
MYOCARDIAL I/R INJURY
In a typical clinical scenario, a patient of middle-
advanced age has various risk factors, comorbidities,
and comedications (72) and has a coronary circulation
that has already undergone functional and structural
remodeling before STEMI (73). The affected individ-
ual may or may not have a developed collateral cir-
culation (74), a history of episodes of prodromal
angina that may induce protection by ischemic pre-
conditioning (75,76), or prior coronary micro-
embolization that has induced patchy microinfarcts
(39). STEMI is usually initiated by the sudden rupture
of an atherosclerotic plaque and more-or-less com-
plete occlusion of an epicardial coronary artery, most
often followed by spontaneous or interventional
reperfusion, but sometimes occurring without reper-
fusion (17). Because all of these factors contribute to
the ﬁnal infarct size, it is clear that no animal model
can recapitulate a clinical scenario exactly. However,
most of our knowledge about myocardial infarction is
derived from studies in anesthetized, young, healthy
animals subjected to sudden coronary occlusion and
reperfusion. Animal models are critical to our un-
derstanding of the pathophysiology of human con-
ditions, but the information obtained with any
particular model can only solve a part of the puzzle.
There is thus no superior animal model, and each has
its uses. Rodent models help to identify potential
mechanisms, but their huge anatomic/physiological
differences from humans make it imprudent to
extrapolate results to the clinical setting. Pilot clinical
trials are justiﬁed only when solid and incontestable
beneﬁts are found in large-animal models with a
much closer match to human anatomy and physi-
ology. The history of cardiovascular medicine is lit-
tered with failed clinical experiences caused by
taking shortcuts from this translational path.
VALUE OF SMALL ANIMAL MODELS OF MYOCARDIAL
INFARCTION. Mice are increasingly used in experi-
mental infarct studies for their ease of breeding, their
low cost, and the availability of transgenic models.But, translation of results is highly limited because of
their high heart rate (an order of magnitude higher
than that of humans) and the small size of their
hearts, which ensures that, during permanent coro-
nary occlusion, the inner myocardial layers continue
to be served with oxygen and nutrients by diffusion.
Thus, infarction in mice develops within 45 to 90 min
(77,78), but no more than 70% of the AAR is infarc-
ted even with permanent coronary occlusion (79).
Rodents generally have a higher heart rate than larger
mammals, but whereas rats and rabbits have little
collateral blood ﬂow and fast infarct progression (80),
guinea pigs have substantial collateral blood ﬂow and
very little infarct progression (81). Signiﬁcant differ-
ences in the response to myocardial infarction are
also found across different mice strains. Depending
on the genetic background, infarct size after the same
procedure can vary by 30% (82).
LARGE ANIMAL MODELS OF MYOCARDIAL INFARCTION.
Large animals are the obligatory step before initi-
ating human trials. Among the larger mammals, pigs
and primates have little collateral blood ﬂow,
whereas cats and especially dogs have a sizeable
innate collateral circulation (81). In pigs, infarction
starts after 15 to 35 min of coronary occlusion and
spreads such that, after 60 to 180 min, infarction is
complete and affects more than 80% of the AAR
(83,84). Tolerance to I/R varies notably across
different pig strains. Primates show a surprising
resistance to infarction, with little or no infarction
evident after 40 to 60 min of coronary occlusion, and
even after 90 min of occlusion, the infarct size is
smaller than that in pigs (85). In dogs, infarction is
largely subendocardial after 40 min of coronary oc-
clusion and progresses to affect about 70% of the AAR
after 6 h, but even permanent occlusion leaves a small
zone of viable myocardium in the subepicardium
(13,14). Given the variable but signiﬁcant collateral
blood ﬂow in dogs, infarct size is best quantiﬁed as a
fraction of the AAR and by its inverse relation to the
residual blood ﬂow (17). Notwithstanding the con-
founders detailed previously (age, comorbidities,
comedication), infarct development in humans ap-
pears to be slower than in these large mammals. From
contrast-enhanced CMR analysis (86–88) and the
amount of salvageable ischemic myocardium at the
time of reperfusion (89,90), one can grossly estimate
that about 30% to 50% of the AAR remains viable
after 4 to 6 h from the onset of anginal symptoms.
Even after 12 h of coronary occlusion, interventional
reperfusion can signiﬁcantly limit infarct size (91). It
is currently unclear whether the slower infarct
progression in humans than in larger mammals is
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that in dogs (74), a species-speciﬁc greater resistance
to infarction as in primates (85), pre-infarction anginal
episodes that protect by ischemic pre-conditioning
(76), some degree of short-term hibernation with
contractile and metabolic adaptation to the reduced
blood ﬂow (92,93), or background medication, notably
with platelet inhibitors (94).
Aside from the differences between animal models,
there are other important factors that must be
considered when performing pre-clinical studies and,
more importantly, when comparing results from
different models or even different laboratories. For
example, the time of the day at which I/R occurs has a
signiﬁcant inﬂuence in the tolerance of the heart to
I/R. After the initial demonstration in mice, this
phenomenon has also been observed in patients (95).
Similarly, the season and even the day of the week
might have an effect on the results observed in ani-
mal models and, eventually, in the response to pro-
tective therapies.
THERAPIES TO REDUCE ISCHEMIC INJURY
Four landmark studies published more than 30 years
ago, 2 experimental and 2 clinical, changed the course
of STEMI treatment in less than a decade, leading
to the huge development of strategies to reduce
ischemic injury.
1. The demonstration of a spatial progression of ne-
crosis during an infarction. Reimer et al. (13,14)
subjected anesthetized dogs to coronary occlu-
sion of various duration and reported the pro-
gression of a wave front of myocardial necrosis
from the central subendocardial layers, where
ischemia is most severe, to the less ischemic lateral
boundaries of the AAR and the subepicardium.
2. The demonstration of the reduced infarct size with
reperfusion. Maroko et al. (18) and Ginks et al. (19)
ﬁrst demonstrated the existence of myocardial
salvage by reperfusion at 3 h after coronary oc-
clusion (“time is muscle”).
3. The unequivocal demonstration that coronary
thrombosis is present in most cases of ongoing
STEMI. DeWood et al. (96) reported detailed
angiographic ﬁndings in patients studied shortly
after the onset of STEMI.
4. The ﬁrst experience with the administration of
intracoronary thrombolytics (streptokinase), as
reported by Chazov et al. (97) and later, in a larger
group of patients, by Rentrop et al. (98).
The conclusions reached, although obvious today,
were revolutionary when these studies werepublished. We now take for granted that STEMI is
generally caused by an acute thrombotic occlusion of
an epicardial coronary artery and that timely recan-
alization of the occluded artery salvages jeopardized
ischemic but still viable myocardium. Thirty years
ago, such notions were thought by many to be he-
retical. Figure 1 summarizes the most relevant land-
marks in the history of STEMI therapy (20).
The development of reperfusion as a therapy for
limiting ischemic damage during STEMI is 1 of the
greatest success stories in the treatment of human
disease. Before this paradigm was established, early
mortality was z20%; for example, the mortality rate
in the control group of the GISSI-1 (Gruppo Italiano
per lo Studio della Streptochinasi nell’Infarto Mio-
cardio) trial was 18% (99). This ﬁgure has since
declined to reach z5% in recent randomized clinical
trials focusing on either pharmacological revascular-
ization, mechanical revascularization, or both. Aside
from reperfusion itself, the progressive reduction in
the time between STEMI diagnosis and reperfusion
has made an important contribution to this reduced
mortality. Following the “time is muscle” principle,
huge efforts have been made to ensure early reper-
fusion. It is now widely accepted that the shortening
of door-to-balloon time (the time between ﬁrst med-
ical contact and mechanical reperfusion) results in
greater myocardial salvage and better outcomes. A
major multidisciplinary effort has resulted in a sig-
niﬁcant decline in door-to-balloon times over the last
10 years in all registries. However, despite these im-
provements, a large U.S. study of almost 100,000
STEMI patients found that in-hospital mortality has
remained unchanged, indicating the need to target
other components of the total ischemic time (3) and
other factors that contribute to infarct size.
REPERFUSION BY PRIMARY PERCUTANEOUS CORONARY
INTERVENTION, THROMBOLYSIS, OR BOTH. Reperfu-
sion is the most effective therapy ever developed
against ischemic damage during STEMI. Pharma-
cological, mechanical, and combined reperfusion
techniques have been reﬁned over the years, and their
efﬁcacy has been greatly advanced by the develop-
ment of adjunctive therapies. The use of lytic agents
in placebo-controlled trials was pivotal in the eluci-
dation of the beneﬁts of sustained reperfusion. The
ﬁrst large-scale trial to deﬁnitively show a signiﬁcant
reduction in mortality by reperfusion with intrave-
nous administration of thrombolytic agents was the
landmark GISSI-1 trial (99). This study was followed
by other landmark trials in the ﬁeld (100,101).
Another revolution in the search for improved
therapies to reduce the ischemic damage associated
FIGURE 1 Landmarks in STEMI Therapy
Landmarks in
therapies to reduce
reperfusion injury
Landmarks in
therapies to reduce
ischemic injury
1972: First evidence
that reperfusion
limits extent
of necrosis.18,19
1980: Unequivocal
demonstration:
coronary thrombosis
cause STEMI.96
1986: First evidence
that ischemic pre-
conditioning reduces
infarct size.116
1993: First
 evidence that 
RIC reduces
infarct size.119
2005: First-in-man 
post-conditioning
reduces infarct
 size in STEMI.89 2013 Proof-of-
concept: metoprolol
reduces infarct size
& increases LVEF
in STEMI.86,128
2008 Proof-of-
concept: CsA
reduces infarct
size in STEMI.90
2010 Proof-of-
concept:
RIC increases
myocardial 
salvage in
STEMI.121
2003: First evidence
that post-conditioning
reduces infarct size.23
1976: First-in-man
intracoronary
thrombolysis in
STEMI.97
1983: First-in-man
primary angioplasty
in STEMI.102
2003: Meta-analysis show
mortality benefits of
primary angioplasty over
thrombolysis in STEMI.103
1977: Wavefront
(endo to epi)
progression of
necrosis.14
1986: GISSI trial:
thrombolysis
reduces mortality
in STEMI.99
1993: GUSTO-Ι trial:
tPA reduces mortality
compared with SK in
STEMI.100
1970s 1980s 1990s 2000s 2010s
1988: ISIS-2 trial:
aspirin improves
outcomes in 
STEMI.109
Some of the most relevant landmarks in the quest for therapies to reduce ischemic- (top, blue) and reperfusion-related (bottom, green) injuries
are represented. Landmarks chosen represent those with a greater effect on clinical practice (there are many other mechanistic landmarks not
represented in the ﬁgure because they have not yet reached the clinical arena). As suggested by the gray arrow, during the early years of this
quest against ischemia/reperfusion injury, most of the efforts and discoveries were in the ischemic-injury side. In the last decades, and after the
ischemic damage was very well approached by clinically available therapies, reperfusion injury therapies have started to arise. The proof-of-
concept era for therapies targeting ischemic injury was in the 1970s, and the large trials arose in the 1980s. For reperfusion injury-targeting
therapies, the proof-of-concept era was in the late 1990s and 2000s, and it is expected that large trials testing the effect of therapies to
reduce reperfusion injury will be undertaken in the 2010s. CsA ¼ Cyclosporin-A; endo ¼ endocardial; epi ¼ epicardial; LVEF ¼ left ventricular
ejection fraction; RIC ¼ remote ischemic conditioning; SK ¼ streptokinase (thrombolytic); STEMI ¼ ST-segment elevation myocardial infarction;
tPA ¼ recombinant tissue-type plasminogen activator (thrombolytic).
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percutaneous coronary intervention (PCI). PCI for
STEMI (primary angioplasty) was ﬁrst described as a
rescue intervention in cases in which thrombolysis
was unsuccessful. It was also implemented widely as
adjunctive therapy to thrombolysis, and it was per-
formed systematically to evaluate the coronary
anatomy and residual stenosis or electively in cases of
spontaneous or inducible angina days after successful
thrombolysis. The use of primary angioplasty as an
alternative to thrombolysis was ﬁrst described in
1983 (102).
The many studies comparing these strategies leave
no doubt that timely PCI by an experienced team issuperior to in-hospital thrombolytic therapy (103).
Furthermore, progress in stent therapy has markedly
reduced the incidence of acute and late stent throm-
bosis (104) and reﬁned the primary PCI strategy.
Despite the clear advantages of PCI over thrombolysis
in head-to-head comparisons, the clinical scenario
is sometimes more complicated. Although no pro-
spective studies have been performed to prove it,
primary PCI may not exhibit a mortality advantage
over immediate thrombolysis when performed after a
delay of 120 min. In some patients (those who present
early with a large AAR and a low bleeding risk), this
maximum acceptable delay may be signiﬁcantly
shorter (105).
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developed for patients who cannot get timely PCI is to
follow the classical thrombolytic therapy and delay
the planned PCI until 3 to 24 h after lytic adminis-
tration (this differs from the facilitated approach, in
which PCI is performed as soon as the patient arrives
at the PCI center). In the STREAM (Strategic Re-
perfusion Early After Myocardial Infarction) trial,
pre-hospital administration of the thrombolytic ten-
ecteplase (half-dose in the elderly) to z2,000 STEMI
patients who could not get PCI within 1 h resulted in
rates similar to standard primary PCI for the com-
posite of death, shock, congestive heart failure, or
reinfarction at 30 days (106). One-year mortality rates
in the 2 groups were almost identical (107). This
approach needs to be further explored in patients
with long transport times to the PCI hospital.
The use of adjunctive antithrombotic agents with
thrombolytics is predicated on the fact that the in-
tensity and net extent of thrombolysis reﬂects a
competition between lysis and ongoing thrombosis
(108). Convincing evidence of the effectiveness of
aspirin as an adjunctive agent was ﬁrst acquired in
the ISIS-2 (Second International Study of Infarct
Survival) trial (109), in which the beneﬁts of aspirin
and streptokinase were additive. Aspirin has also
been used as an adjunctive therapy in STEMI in
patients undergoing reperfusion by primary PCI.
Further clinical beneﬁts are obtained by supple-
menting aspirin with new antiplatelet agents such as
clopidogrel, ticagrelor, or prasugrel. Given the clear
beneﬁcial effect of optimal antiplatelet therapy in
STEMI, it should be implemented in the testing of
any cardioprotective strategy. Further information
on reperfusion strategies and adjunctive pharmaco-
logical therapy can be found in dedicated review
papers (20).
OTHER THERAPIES TO REDUCE ISCHEMIC INJURY.
The possibility of slowing the progression of ischemic
damage during ongoing ischemia has been investi-
gated for several decades. Drugs able to reduce oxy-
gen consumption have been tested in randomized
clinical trials. Among them, b-blockers were widely
evaluated in many STEMI trials, but no clear reduc-
tion in infarct size was detected, bringing the car-
dioprotective potential of b-blockers in STEMI into
question. However, all of these trials addressing the
effect of b-blockers on infarct size, with the exception
of 1 (110), were performed in patients not under-
going reperfusion. More recently, interest in the
b1-selective blocker metoprolol has been revitalized
due to its demonstrated ability to minimize reperfu-
sion injury (discussed in the following text).Hypothermia has been unequivocally shown to
reduce the rate of progression of ischemic damage in
animal models of STEMI (111), but clinical application
of hypothermia has been extremely challenging due
to the lack of a safe cooling procedure able to reduce
temperature fast enough to affect ischemic damage
(well before reperfusion). After several small studies,
the CHILL-MI (Rapid Endovascular Catheter Core
Cooling combined with cold saline as an Adjunct to
Percutaneous Coronary Intervention For the Treat-
ment of Acute Myocardial Infarction) trial recruited
120 STEMI patients scheduled for PCI and randomized
them to standard care or a rapid cooling protocol
(infusion of cold saline plus endovascular cooling
device). Hypothermia did not reduce infarct size
(normalized to AAR) as measured by CMR (112), de-
spite achievement of the target temperature (<35C)
in >75% of patients at the time of reperfusion.
Attaining signiﬁcant reductions of ischemic damage
(and infarct size) with hypothermia would require
the target temperature to be reached long before re-
perfusion. With the signiﬁcant reductions seen in
door-to-balloon times, this seems very unlikely to be
achieved with the available techniques.
THERAPIES TO REDUCE
REPERFUSION INJURY
Although the history of therapies to reduce ischemic
damage, mostly involving reperfusion therapy, is full
of rapid successes, the development of therapies to
reduce reperfusion injury has been disappointing. This
disparity reﬂects the contrast between the straight-
forward problem presented by reducing ischemic
injury (restoration of blood ﬂow) and the more com-
plex processes associated with reperfusion injury.
THE LONG DEBATE IS COMING TO AN END: LETHAL
REPERFUSION INJURY IS A REALITY. The term
“reperfusion injury” has been used for many decades
to describe several events associated with reperfu-
sion, some transitory (e.g., ventricular arrhythmias,
myocardial stunning, and so on) and others perma-
nent (e.g., death induced by reperfusion, known as
lethal reperfusion injury). The existence of lethal
reperfusion injury in STEMI has long been a matter of
debate (24,113). Despite the convincing experimental
evidence already outlined in this review, deﬁnitive
clinical demonstration has been lacking. This is partly
due to the gap between well-deﬁned and controlled
experimental models on the one hand and unclear
human proofs-of-concept (i.e., “clinical models”) and
trial designs on the other (114). Negative ﬁndings in
infarct size reduction trials accumulated, giving cur-
rency to the idea, common among cardiologists and in
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was either a fantasy or at best a laboratory artifact.
Studies in the early 1990s showed that reperfusion
did not increase the transmural extent of infarction in
canine hearts, suggesting an absence of reperfusion
injury (115). The dog is a particular case, however, in
which injury progresses slowly, and 90 to 180 min of
coronary occlusion might not provoke signiﬁcant
reperfusion injury; it is known that ischemic and
reperfusion injuries are linked, the degree of the
former determining the extent of the latter. The idea
of lethal reperfusion injury has since won progressive
acceptance on the basis of evidence coming from
clinical and basic science studies. Lethal reperfusion
injury can be deﬁned as a potentially preventable
death of myocardium that was viable at the time of
reperfusion and that is the consequence of events
triggered or magniﬁed by reperfusion. The fact that
preventive maneuvers like post-conditioning limit
infarct size without affecting ischemic injury is the
best demonstration of the reality of lethal reperfusion
injury.
NONPHARMACOLOGICAL INTERVENTIONS TO REDUCE
REPERFUSION INJURY. The ﬁrst major breakthrough
in nonpharmacological interventions was the deﬁni-
tion of “ischemic pre-conditioning” by Murry et al.
(116), who, in 1986, reported that brief cycles of
ischemia and reperfusion performed before a pro-
longed coronary artery occlusion with reperfusion
could dramatically reduce ﬁnal infarct size in dogs.
Given that total ischemic time was unaltered (even
increased) by this intervention, this study suggested
that there was more to limiting infarct size than a
shorter duration of ischemia. This ﬁnding ushered in
a paradigm shift, which stimulated a wave of research
that has increased our understanding of the patho-
physiology of I/R injury at the molecular level,
thereby preparing for the identiﬁcation of new targets
for future innovative therapies. Many years later, the
infarct-limiting effects of ischemic pre-conditioning
were shown to be due to a large extent to a reduc-
tion in reperfusion injury (117), although it is also
plausible that pre-conditioning can reduce ischemic
damage. The unpredictability of coronary artery oc-
clusion in STEMI patients means that ischemic pre-
conditioning cannot be applied in this clinical
setting, but it could have an important role in plan-
ned procedures like cardiac surgery (8,75). The sec-
ond breakthrough was the description of “ischemic
post-conditioning” by Zhao et al. (23) in 2003. They
showed that brief episodes of ischemia and reperfu-
sion performed immediately after reﬂow following
prolonged ischemia could reduce ﬁnal infarct size in
dogs by 30% to 40% (23). This effect was even moresurprising than pre-conditioning, because the inter-
vention was applied after reﬂow; thus, it has no
connection to the duration of ischemia or any asso-
ciated event and must be related to the prevention of
events occurring after reperfusion. With this simple
experiment, this group demonstrated that lethal
reperfusion injury is a reality (24), is quite signiﬁcant
in an experimental setting (30% to 40% of ﬁnal infarct
size), and that it is amenable to timely intervention.
With these breakthroughs, the time had come to
test whether lethal reperfusion injury could be
attenuated in STEMI patients. The ﬁrst to do so were
Staat et al. (89), who demonstrated in 2005 that
ischemic post-conditioning can reduce infarct size in
STEMI. In this proof-of-concept trial, ischemic post-
conditioning was applied within 1 min after reﬂow
by inﬂating/deﬂating the angioplasty balloon (low-
pressure, upstream of the stent) in 4 1-min cycles.
This resulted in a 36% reduction of the area under the
curve for creatine kinase release, a surrogate marker
of infarct size. Most, not all, of the small trials
performed have shown infarct size reduction in pa-
tients undergoing post-conditioning (8). However,
the largest randomized clinical trial of post-
conditioning in STEMI was neutral (118). The proto-
col for the POST (Effects of Postconditioning on
Myocardial Reperfusion in Patients With ST-Segment
Elevation Myocardial Infarction) trial allowed the
discretional use of thrombectomy, pre-dilation, and
other maneuvers. The repeated balloon inﬂation-
deﬂation at the site of the culprit lesion might have
been responsible for excessive inadvertent thrombus
microembolization, as suggested by the low rate of
ST-segment resolution. And, although the protocol
stipulated post-conditioning within 1 min of STEMI,
the high frequency of thrombectomy (50%) likely
delayed post-conditioning beyond the protective
1-min time-frame, and this might have diluted the
beneﬁts of this protective strategy. The fact that
the largest trial was neutral calls for caution in the
interpretation of the infarct-limiting effects of post-
conditioning until new trials are completed. In addi-
tion, the details of the POST trial highlight that
application of this strategy in a real-life scenario is
more challenging than in the proof-of-concept trials,
in which patient selection and protocol application is
more controlled. In the DANAMI-3 (Danish Study
of Optimal Acute Treatment of Patients With
ST-elevationMyocardial Infarction-3) (NCT01435408),
2,000 STEMI patients will be allocated to 1 of 3
study interventions: conventional PCI (immediate
stent implantation), post-conditioning (with stent
implantation after the end of 4 30-s post-conditioning
cycles), or deferred stenting (opening the culprit
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and/or low pressure balloon inﬂation and stenting
after 48 h). The combined endpoint will be all-cause
mortality or heart failure at 2 years.
Another form of myocardial conditioning well
described in animal models is remote ischemic con-
ditioning: conditioning performed in a distant organ
(119). Remote ischemic conditioning is reviewed in
detail elsewhere (120). For the purpose of this review,
it is important to mention that remote ischemic pre-
conditioning (4 5-min brachial cuff inﬂations
applied during ongoing STEMI: i.e., during ambu-
lance transfer to the PCI center and before PCI
reperfusion) resulted in increased myocardial salvage
compared with regular PCI (121), and this might
translate into fewer long-term clinical events (122).
The possibility should be conﬁrmed in the ongoing
CONDI-2 (Effect of RIC on Clinical Outcomes in STEMI
Patients Undergoing pPCI) trial (NCT01857414).
PHARMACOLOGICAL INTERVENTIONS TO REDUCE
REPERFUSION INJURY. During the past 10 years,
many phase II clinical trials have been performed to
ﬁnd coadjuvant pharmacological interventions to
ameliorate the myocardial damage associated with
STEMI. We will describe here the most promising
pharmacological strategies as well as examples from
the long list of failures.
DRUGS WITH PROMISING RESULTS IN
PILOT/PHASE II TRIALS
CYCLOSPORINE-A. Because local conditions (coro-
nary anatomy, thrombus burden) can make it difﬁcult
to apply ischemic post-conditioning during PCI,
pharmacological agents that trigger similar pathways
to ischemic conditioning have been extensively
investigated at the pre-clinical level and then trans-
lated into pilot clinical trials (123). Cyclosporine-A
is the paradigm pharmacological post-conditioning
agent. Cyclosporine-A acts by inhibiting the ope-
ning of the MPTP, an event also seen with post-
conditioning. Piot et al. (90) randomized 58 patients
to receive a single bolus of cyclosporine A or placebo
immediately before PCI. Infarct size, measured by the
area under the curve of creatine kinase, was signiﬁ-
cantly smaller in the cyclosporine-A group. The
ongoing multicenter, randomized, placebo-controlled
CIRCUS (Cyclosporine and Prognosis in Acute Myo-
cardial Infarction [MI] Patients) trial (NCT01502774)
recruited 975 anterior STEMI patients (Thrombolysis
In Myocardial Infarction ﬂow grade 0 to 1 left anterior
descending occlusion) and randomized them to cy-
closporine A or placebo. The combined primary
endpoint (total mortality; hospitalization for heartfailure; and LV remodeling [increase of LV end-
diastolic volume >15%]) will be assessed at 1-year
follow-up.
METOPROLOL. The effect of b-blockers on infarct
size in STEMI patients has been intensely debated.
Different b-blocker agents were tested in many STEMI
trials in the 1970s to 1980s with no deﬁnite conclusion
on their cardioprotective effect. However, these trials
were performed before reperfusion became estab-
lished practice, and it is not surprising that b-blockers
showed no consistent infarct limiting effect because,
with no reperfusion, the chances of myocardium
salvage are negligible. In the era of thrombolysis as
the standard treatment for STEMI, the 1 randomized
clinical trial performed showed neutral effects of
intravenous (IV) atenolol on infarct size (110). Pre-
clinical data from the pig model of infarction de-
monstrated that IV metoprolol very signiﬁcantly
reduces infarct size when administered before
reperfusion (124,125). Contrary to the classical theory
of reduced myocardial oxygen consumption, the
mechanism responsible for this infarct-limiting effect
is proposed to be related to a reduction in reperfusion
injury due to the effect of metoprolol on circulating
cells (neutrophils/platelets) rather than cardio-
myocytes (126). This pre-clinical evidence led to the
METOCARD-CNIC (Effect of Metoprolol in Cardio-
protection During an Acute Myocardial Infarction)
trial, in which 270 anterior STEMI patients undergo-
ing PCI were randomized to early IV metoprolol or
control before reperfusion. Infarcts, measured by
CMR, were signiﬁcantly smaller in the IV metoprolol
group (86), and the effect was more pronounced in
patients recruited during ambulance transfer to
the PCI center (127). Six-month CMR follow-up of
more than 200 patients showed that the IV meto-
prolol group had a signiﬁcantly higher mean LVEF
and had signiﬁcantly less cases of severe LVEF
depression (128).
The encouraging results from the METOCARD-
CNIC trial appear to contradict ﬁndings from the
much larger COMMIT (ClOpidogrel and Metoprolol in
Myocardial Infarction Trial). In this mega trial, STEMI
patients undergoing thrombolysis were randomized
to early IV metoprolol followed by oral metoprolol or
matching placebo. The COMMIT trial did not report
data on infarct size; yet, it showed signiﬁcantly
reduced rates of reinfarction and ventricular ﬁbrilla-
tion in response to early IV metoprolol, but this was
counterbalanced by an excess cardiogenic shock,
resulting in a net neutral effect on mortality (129).
However, treatment of patients in the COMMIT trial
was not optimal according to current guidelines.
First, STEMI patients received thrombolytic therapy
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amount of myocardial salvage that can be achieved
after 10 h of coronary occlusion is residual at
best, especially when thrombolysis is used as the
reperfusion strategy (130). Second, the COMMIT trial
included STEMI patients in Killip class III, who
received the full regime of metoprolol administra-
tion; metoprolol resulted in relative mortality re-
ductions of 5% and 2.5% in Killip class I and II
patients, respectively, but increased mortality by 19%
in Killip class III patients. Finally, metoprolol also
increased mortality in patients with systolic blood
pressure <120 mm Hg. These results reinforce the
contraindications for IV b-blocker therapy in patients
with overt heart failure or who are hemodynamically
compromised, who have been systematically ex-
cluded from other b-blocker studies. In contrast
with COMMIT, the METOCARD-CNIC trial recruited
early presenters (<6 h from STEMI onset), and
patients with Killip class $III were excluded.
The patient population in the METOCARD-CNIC trial
is thus more representative of the current standard of
care for STEMI patients. The ongoing EARLY BAMI
(Beta-blocker Administration before primary PCI in
patients with ST-elevation Myocardial Infarction)
trial (131) is testing the infarct-limiting effects of IV
metoprolol in STEMI patients recruited during
ambulance transfer to the PCI center, with a similar
design to METOCARD-CNIC, except that it includes
patients with infarcts in any location (METOCARD-
CNIC recruited only patients with anterior STEMI)
and extends the time window for recruitment to 12 h
(compared with 6 h in METOCARD-CNIC). Finally,
the hard endpoint-powered MOVE ON! (Impact of
pre-reperfusion Metoprolol On clinical eVEnts after
myocardial infarctiON) trial will deﬁnitively answer
whether the amelioration of I/R injury exerted by
early IV metoprolol (132) translates into a real clin-
ical beneﬁt. Given that not all b-blockers have the
same intracellular effects (due to their disparate
lipophilicity among other differences) and do not
even share the same mechanistic effect (despite be-
ing considered b1 selective), it should not be
assumed that all will have similar infarct-limiting
effects.
GLUCOSE MODULATORS. The possible therapeutic
use of glucose to protect cardiomyocytes from energy
depletion during myocardial infarction was proposed
several decades ago by Sodi Pallares et al. (133).
Combined administration of glucose/insulin/potas-
sium (GIK) during ongoing myocardial infarction has
been tested in several trials with some encouraging
results. The IMMEDIATE (Immediate MyocardialMetabolic Enhancement During Initial Assessment
and Treatment in Emergency Care) trial recruited
patients with suspected acute coronary syndrome
and randomized them to GIK or placebo during
transfer to the hospital. In the subgroup of patients
presenting with STEMI, GIK signiﬁcantly reduced
CMR-evaluated infarct size (134). However, these
promising results need to be conﬁrmed in a pro-
spective trial powered to detect differences in infarct
size. Another approach has been the use of glucagon-
like peptide-1 (GLP1) analogs. After promising pre-
clinical results, Lonborg et al. (135) randomized 172
STEMI patients to receive IV injection of the GLP1
analog exenatide or placebo. Myocardial salvage on
CMR was signiﬁcantly higher in the exenatide group
(135).
ABCIXIMAB. Glycoprotein IIb/IIIa inhibitors were
developed for the reduction of thrombotic events due
to their potent effect on platelets and platelet-
leukocyte aggregates implicated in I/R injury. The
INFUSE-AMI trial recruited 452 anterior STEMI pa-
tients undergoing PCI and performed an open-label,
22 factorial randomization to test the effect of
abciximab and/or thrombectomy on infarct size, as
evaluated by CMR. Thrombus aspiration had no effect
on infarct size, but intracoronary administration of
abciximab signiﬁcantly reduced infarct size (136).
Given that the current standard of care for STEMI
patients includes the use of potent oral antiplatelet
agents, glycoprotein IIb/IIIa inhibitors are left for a
selected STEMI population.
EXAMPLES FROM THE LONG LIST OF
FAILED CLINICAL TRIALS FOR REDUCING
REPERFUSION INJURY
Many clinical trials have attempted and yet failed to
demonstrate the ability of a given therapy to limit
infarct size by reducing reperfusion injury. A common
denominator in many of these failures is the weak or
unclear beneﬁt in the pre-clinical phase (137,138). A
description of all of the negative trials in the ﬁeld is
beyond the scope of this review; here, we provide an
update on the more recent negative trials.
Adenosine has been evaluated in several trials and
did not show a clear infarct-limiting effect. In the most
recent trials, adenosine was administered by intra-
coronary injection at high doses, and myocardial
salvage was evaluated by CMR. Adenosine had no ef-
fect on myocardial salvage or MVO (87,139). The effect
of inhaled nitric oxide on infarct size in 250 STEMI
patients undergoing PCI was very recently tested in
the NOMI (Nitric Oxide for inhalation to reduce
reperfusion injury in acute STEMI) trial (140). Nitric
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ated by CMR. The effect of IV sodium nitrite on infarct
size was evaluated in 229 STEMI patients undergoing
PCI in the NIAMI (Intravenous sodium nitrite in acute
ST-elevation myocardial infarction: a randomized
controlled trial) trial (141). The authors did not ﬁnd
any difference in infarct size as evaluated by CMR, the
primary endpoint of the study. The effect of intrave-
nous TRO40303, a drug binding to an unclear molec-
ular target in the outer mitochondrial membrane,
was tested in the MITOCARE (Effect of intravenous
TRO40303 as an adjunct to primary percutaneous
coronary intervention for acute ST-elevation
myocardial infarction) trial as an adjunct to primary
percutaneous coronary intervention for acute STEMI.
This study of 163 STEMI patients randomized to
TRO40303 or placebo found no differences in infarct
size either by biomarker release (primary endpoint)
or CMR. Salvage index by CMR was also not different
between groups (142). Several other trials have
shown negative results in the past (reviewed in more
detail by Kloner [9]).
CLINICAL TRIALS TARGETING
ISCHEMIA/REPERFUSION INJURY:
IMPORTANCE OF ENDPOINTS
Incorporation of new clinical evidence into clinical
practice guidelines requires the demonstration of a
clear clinical beneﬁt (an effect on hard endpoints).
This demonstration usually requires large phase III
trials. Given the high costs associated with large tri-
als, the natural next step after obtaining strong pre-
clinical data is to perform a pilot (phase II) clinical
trial. These small trials usually choose a primary
endpoint accepted as a surrogate for hard clinical
endpoints. Infarct size is the most intuitive parameter
evidencing the cardioprotective effect of a given
intervention and also correlating with clinical
events. More importantly, it is well-deﬁned in animal
models, where it is recognized as the hallmark of
cardioprotection. Although single photon emission
computed tomography (121), electrocardiogram pa-
rameters (118), and biomarker release (90) have been
widely used, CMR-measured infarct size is currently
the most widely recommended technique for assess-
ing infarct size in STEMI trials. LVEF is the classical
surrogate functional parameter, because it has been
clearly associated with long-term mortality and
morbidity after STEMI (143). In addition to infarct
size, other readouts of reperfusion injury or de-
terminants of infarct size can be measured to more
accurately evaluate protective interventions. For
example, MVO is associated with poor clinicaloutcomes when evaluated by various techniques,
mainly CMR (27,144). AAR has been used in recent
trials to normalize infarct size or to depict myocardial
salvage (% of AAR with no infarction). AAR can be
estimated by angiographic means (BARI [Bypass An-
gioplasty Revascularization Investigation Myocardial
Jeopardy Index]/APPROACH [Alberta Provincial
Project for Outcome Assessment in Coronary Heart
Disease] coronary angiographic scores or LV angio-
graphic scores) or by T2-CMR. Although T2-CMR is
increasingly used, its capacity to depict true AAR is
debated (the pros and cons of the use of CMR to de-
pict AAR are reviewed elsewhere [145,146]). Some
studies have reported a prognostic value of myocar-
dial salvage (147); however, this parameter has not
been extensively validated. Myocardial salvage is a
surrogate of infarct size used to control for variations
in AAR between study groups. In addition, very
recently, therapies that reduce infarct size, like post-
conditioning (148) and remote conditioning (149),
were shown to reduce CMR-evaluated AAR. Studies of
remote ischemic conditioning and the GLP1 analog
exenatide have shown increases in myocardial
salvage, but no signiﬁcant effect on infarct size or
LVEF (121,135). These results should, moreover, be
interpreted with caution, because the real surrogate
markers of hard clinical endpoints were neutral. Tri-
als using infarct size (a known surrogate of clinical
events) as an endpoint are easier to interpret than
trials using myocardial salvage (a surrogate of a sur-
rogate of clinical events). The use of CMR to visualize
post-infarction edema has recently been made more
complex by the demonstration that the edematous
reaction of the myocardium to ischemia/reperfusion
is bimodal (150). Comprehensive serial CMR evalua-
tion in pigs showed that there are 2 independent
waves of edema after ischemia/reperfusion: an initial
wave appearing abruptly upon reperfusion, and a
deferred wave occurring a few days later (150). This
bimodal post-ischemia/reperfusion edematous reac-
tion highlights the need for caution in the use of CMR
to visualize edema as a marker of ischemic memory.
Sample size calculation for clinical trials is based
on the anticipated treatment effect on a principal
outcome (a reduction or increase in the experimental
arm vs. control). Normally, several additional sec-
ondary endpoints are prospectively evaluated. It is
important to stress that when the primary endpoint of
a trial is negative, all other ﬁndings are exploratory at
best, and the secondary outcome, if relevant, should
be tested in a dedicated trial. It is also important to
highlight the risk of overinterpreting subgroup ana-
lyses. Some of the phase II trials described here as
negative have “exploratory” analyses in which
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early) show a positive result. These analyses are biased
because the subgroup was not randomized, and
thus, the results could be affected by potential un-
known confounders. This is especially true when
the overall population does not show a signiﬁcant
treatment effect. The interpretation of endpoints in
clinical trials was recently reviewed by Pocock and
Gersh (151).
Other relevant questions regarding the selection of
populations for clinical trials are related to the better
identiﬁcation of potential responders according to
the expected mechanism of the study intervention.
The response to protective agents administered at
reﬂow appears to vary according to the duration of
ischemia, and some trials using pharmacological
agents suggest that only patients with short duration
of ischemia can beneﬁt (112). This suggests that the
dynamics of lethal reperfusion are inﬂuenced by
the duration of the preceding ischemia and are
probably not linear. In addition, indirect evidence
suggests that age, sex, comorbidities (e.g., diabetes,
hypertension, smoking), and cotreatments (statins,
antiplatelet agents) may have an effect on infarct sizeand on protection by conditioning interventions
(94,152).
THE FUTURE
Over the past decades, important progress has been
made in the quality of phase II trials evaluating
protective interventions against lethal reperfusion
injury. Although these trials will always be a man-
datory preliminary step, the challenge of the next
decade is to set up larger phase III trials evaluating
clinical outcomes to therapies targeting lethal reper-
fusion injury. As in other disciplines, we envision that
the advances in the next decade will come from
reﬁning the therapies already available rather that
identifying new drugs. The commitment of funding
agencies, scientiﬁc societies, and industrial partners
is needed to achieve this challenging goal.
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